Kura Oncology Inc. held a presentation focusing on their investigational menin inhibitor, Ziftomenib, targeted at treating relapsed/refractory and newly diagnosed acute myeloid leukemia $(AML.AU)$. The presentation highlighted the positive results from the Phase 2 KOMET-001 trial, which led to a New Drug Application (NDA) for Ziftomenib. This NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025. The presentation also discussed the Ziftomenib Global Development Plan, including the KOMET-017 Phase 3 clinical trials and the market opportunity for newly diagnosed NPM1-m and KMT2A-r AML patients. Key opinion leaders such as Dr. Harry Erba and Dr. Ghayas C. Issa participated in the event. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。